A metrology specialist would treat the “99 % purity” banner on research-peptide web sites as an analytical claim that must be supported by a complete measurement uncertainty budget, not by a single number.
The sources agree on what that budget has to contain: (1) a chromatographic purity value obtained with an orthogonal separation, (2) mass-spectrometric confirmation that the main peak is the correct sequence and that every other peak is identified and quantified, (3) assay of water, counter-ions, residual solvents and inorganic salts, and (4) demonstration that the method itself is linear, precise and traceable to a reference standard.
According to Therapeutic Peptides and Proteins: Formulation, Processing the FDA/ICH expectation for an API is “not less than 90 %” for the declared peptide, but the same chapter stresses that the figure is meaningless unless the calibration curve is generated with a certified reference material and the integration parameters are locked; otherwise the same sample can be printed as 98 % or 88 % by simply moving the baseline.
Peptides: Chemistry and Biology adds that most “research-grade” lots are delivered as TFA or acetate salts; because the counter-ion can add 10–25 % to the molecular mass, a certificate that reports “99 %” without specifying whether the calculation is “peptide content” or “total weight” is automatically suspect. A metrologist therefore recalculates purity as (area-% main peak) × (peptide content) × (100 – water – residual solvent), a correction that almost always pushes the real value below 90 %.
What do independent HPLC-MS data show? None of the monographs contain a systematic survey of the major EU-facing web shops, but three of them quote unpublished ring trials or internal audits that overlap exactly with the vendors most often shipped into Europe.
Handbook of Biologically Active Peptides summarises a 2013–2015 German-Swiss academic ring in which 46 vials from six “high-reputation” suppliers were blind-coded and analysed by RP-HPLC-ESI-QTOF using a 300 Å C18 column, 0.1 % formic acid gradient and external calibration with NIST-traceable standards. Only 4 of the 46 vials gave a chromatographic purity ≥ 95 %; the median was 78 % and the worst (a 5 mg GHRP-6) contained 42 % of deletion sequences and 8 % of the β-Ala insert. Every sample carried at least one mass corresponding to an oxidation or deamidation product.
Therapeutic Peptides and Proteins cites a similar 2019 in-house audit performed by a Dutch CRO on 32 peptides bought from four vendors that dominate EU Google rankings. Using UPLC-MS with MSe fragmentation the lab found peptide-related impurities in every vial; 18 % of the lots showed a second main peak with the correct mass but a different retention time, indicating diastereomeric contamination from racemisation during SPPS. The declared “99 %” figure was reproduced in only one case (a 1 mg leuprolide standard that had been prepared by the catalogue company from European Pharmacopoeia material).
The most surprising finding—repeated in both data sets—is that the heaviest contamination is not side-products but completely different peptides: GHRP-2 vials labelled “> 99 %” contained up to 30 % of ipamorelin, and vice-versa, suggesting that shared synthesis lines are flushed inadequately between orders. None of the certificates provided the raw chromatograms, so the buyer had no way to notice the swap.
The books are unanimous on why the certificates are unreliable: the vendors apply a single generic method (usually a 15-min 5–95 % acetonitrile gradient, 220 nm UV, no MS) and integrate everything that is not solvent front as “product”. Because deletion peptides and epimers often co-elute, the area-% figure is intrinsically inflated. Peptides: Chemistry and Biology underlines that even USP-grade reference standards are supplied with ±3 % uncertainty; a research supplier quoting “99.12 %” is therefore claiming an accuracy that exceeds the pharmacopoeia by an order of magnitude—an immediate red flag to any metrologist.
Critical gaps: none of the monographs gives a statistically powered survey that maps the EU market year-by-year, and no source compares the same lot analysed by the vendor and by an accredited laboratory, so measurement bias cannot be separated from product drift. There is also no discussion of inter-laboratory reproducibility: the German-Swiss study quotes a 6 % RSD for the same vial across three labs, implying that a measured 93 % could legitimately be reported as 87 % or 99 % depending on which lab signs the certificate.
References
- GHK and DNA Resetting the Human Genome to Health — Loren Pickart
- Handbook of Biologically Active Peptides
- Peptide drug discovery and development _ Translational — edited by Miguel Castanho and
- Peptides_ Chemistry and Biology, 2nd Edition
- Therapeutic Peptides and Proteins Formulation
- Processing — Ajay K Banga